Project Grant R43NS108869

This $999,998 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports the development of Renerva LLC's Peripheral Nerve Matrix (PNM) technology. PNM is a tissue-based hydrogel derived from porcine nerve that aims to improve functional outcomes for patients with challenging peripheral nerve gap injuries. The Phase I project will optimize the PNM...

This Project Grant awarded by the National Science Foundation (CFDA 47.041 - Engineering) to Cleveland State University (CSU) provides $500,000 in funding from January 1, 2025 to December 31, 2027 to develop bioprinted tissue scaffolds with Schwann cell density gradients and electrical conductivity for peripheral nerve regeneration. The goal is to understand how Schwann cell density gradients and electrical properties within the scaffolds can enhance the regeneration of injured peripheral...

Renerva LLC, a for-profit manufacturer, is developing peripheral nerve matrix (PNM) technologies to facilitate functional recovery in animal models of direct muscle neurotization (DMN) through a $494,955 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The two-year project aims to 1) optimize the formulation of a clinical-grade PNM product to provide...

This Project Grant award from the National Science Foundation (NSF), under the Engineering program (CFDA 47.041), provides $200,000 to Cleveland State University to investigate scaffold degradation for peripheral nerve regeneration. The goal is to develop better ways to control scaffold degradation in order to more effectively support nerve repair and healing. The research will utilize 3D bioprinting to create scaffolds with precise structures and study how scaffold breakdown affects nerve...

This Project Grant award of $1,489,811.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on validating an ex vivo gene correction strategy and ensuring the safety, therapeutic efficacy, and delivery of an autologous cell replacement therapy for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). The award aims to...

The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), has awarded a $500,000 Project Grant to Renerva LLC, a biomedical company in Swissvale, PA. The grant, funded under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of Renerva's PNM-CAP device - a novel, biodegradable nerve capping technology designed to prevent painful neuroma formation in peripheral nerve injuries and amputations. The...

This $540,322 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research at The Ohio State University on the role of 3D chromatin architecture in axonal regeneration following peripheral nerve injury. The objective is to investigate how the folding of the genome into topologically associating domains (TADs) and enhancer-promoter...

This $286,414 Project Grant awarded on September 10, 2025 by the National Institutes of Health (NIH) Office of Research Infrastructure Programs (ORIP) under CFDA 93.351 aims to significantly enhance the efficiency of generating human skeletal muscle in pigs. The primary objective is to develop novel regenerative therapies by producing human skeletal muscle in pigs for reconstructive and transplantation-based surgeries. The grant recipient, Northstar Genomics, LLC, will leverage recent...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) is supporting the development of an optimized, off-the-shelf alternative to autologous fat grafting for soft tissue repair. The $293,983 award to Insoma Bio, Inc., a biotechnology company in Durham, North Carolina, will evaluate the combination of Insoma Bio's Fractomer tissue repair matrix and the Renuva adipose allograft material from MTF...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $385,500 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Leland Stanford Junior University (Stanford University). This 2-year grant, effective February 1, 2025, will support the development of an inducible and multiplexed dual gene modulation CRISPR system to study neuronal activity and regeneration. The goal is to create a synthetic biology...